
Corona Remedies IPO
- Issue price
- ₹1,062
- Listing price
- ₹1,470
- +38.42%
- Current price
- ₹2,329.7
- +119.37%
- Subscribed
- 137.04x
- Issue size
- ₹655.37 Cr
- Listed on
- 15 Dec 2025
IPO timeline
- Opens8 DecMon
- Closes10 DecWed
- Allotment11 DecThu
- Refunds12 DecFri
- Demat credit12 DecFri
- Listing15 DecMon
Issue details
- Price band
- ₹1,008 – ₹1,062 per share
- Issue size
- ₹655.37 Cr
- Fresh issue
- None
- Offer for sale
- ₹655.37 Cr
- Issue type
- OFS only
- Face value
- — per share
- Lot size
- 14 shares
- Minimum investment
- ₹14,868
- Listing on
- BSE, NSE
- Exchange code
- CORONA · 7484
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
Reservation
- QIB
- 30,58,007 shares (50.00% of the Offer)
- NII
- 9,17,403 shares (15.00% of the Offer)
- Retail
- 21,40,606 shares (35.00% of the Offer)
- Employee
- 58,035 shares (0.94% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on KFin Technologies- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 11 Dec 2025
- Refunds initiated
- 12 Dec 2025
- Shares credited to demat
- 12 Dec 2025
- Listing
- 15 Dec 2025
Grey market premium (GMP)
- Current GMP
- ₹300
- +484.00%
- Estimated listing price
- ₹1,362
- Issue price ₹1,062
- Highest
- ₹300
- 6 Jan
- Lowest
- ₹300
- 6 Jan
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 13 Jan 2026 | ₹300 | +484.00% | ₹1,362 |
| 6 Jan 2026 | ₹300 | — | ₹1,362 |
- Kostak rate
- ₹300
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB278.52x
- NII (HNI)208.88x
- Retail28.73x
- Employee14.72x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 12,88,732 | 35,89,39,448 | 278.52x |
| Non-Institutional Investors (NII) | 9,66,549 | 20,18,97,066 | 208.88x |
| bNII — bids above ₹10 Lakh | 6,44,366 | 15,07,93,356 | 234.02x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 3,22,183 | 5,11,03,710 | 158.62x |
| Retail Individual Investors (RII) | 22,55,281 | 6,48,02,038 | 28.73x |
| Employee | 61,320 | 9,02,888 | 14.72x |
| Total | 45,71,882 | 62,65,41,440 | 137.04x |
Financials
- P/E (pre-issue)
- 58.26
- P/E (post-issue)
- 58.26
- EPS (₹)
- 24.43
- RoCE
- 32.55%.
- RoNW
- 24.65%
- PAT Margin
- 12.49-13.33
Pre-issue P/E uses the shares outstanding before the IPO; post-issue P/E includes the new shares. Calculated by Be IPO Ready at the issue price.
| Period ended | 30 jun 25 | 31 mar 25 | 31 Mar 24 |
|---|---|---|---|
| Revenue | 348.56 | 1,202.35 | 1,020.93 |
| OPM % | 24.29 | 23.32 | |
| EBITDA | 71.80 | 245.91 | 161.19 |
| Net Profit | 46.20 | 149.43 | 90.50 |
| Debt | 106.65 | 62.70 | 134.14 |
| Assets | 1,012.38 | 929.86 | 830.58 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Corona Remedies This IPO | ₹655.37 Cr | 58.26 | 24.65% | 12.49-13.33% | 137.04x | +38.42% |
| Fusion CX Mainboard · listed 22 Oct 2026 | ₹702 Cr | 18.73 | 9.12% | 11.36% | 4.45x | +5.54% |
| Senores Pharmaceuticals Mainboard · listed 30 Dec 2024 | ₹582.11 Cr | 28.21 | 23.60% | 15.25% | 96.96x | +53.45% |
| Innova Captab Mainboard · listed 29 Dec 2023 | ₹570 Cr | 36.42 | 24.58% | 7.34% | 56.33x | +0.92% |
| GPT Healthcare Mainboard · listed 29 Feb 2024 | ₹525.14 Cr | 32.49 | 23.77% | 10.64% | 8.52x | +15.59% |
| Suraksha Diagnostic Mainboard · listed 6 Dec 2024 | ₹846.25 Cr | 74.89 | 14.09% | 10.57% | 1.27x | -0.68% |
| Ellenbarrie Industrial Gases Mainboard · listed 1 Jul 2025 | ₹852.53 Cr | 67.69 | 24.97% | 23.90% | 22.47x | +21.50% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Corona Remedies plans to use the money raised, as stated in the offer document.
- BRLMs fees and commissions (including underwriting commission, brokerage and selling commission)₹21.03 Cr
- Fees payable to the Registrar to the Offer₹0.5 Cr
- Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank(s) for Bids made by RIIs using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs₹3.07 Cr
- Advertising and marketing expenses₹2.41 Cr
- Others
- Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees₹7.11 Cr
- Other regulatory expenses
- Printing and stationery expenses₹1.17 Cr
- Fees payable to legal counsels₹8.81 Cr
- Fees payable to other advisors to the Offer, including but not limited to Statutory Auditors, independent chartered accountant, practising company secretary, industry expert₹4.01 Cr
- Miscellaneous₹3.85 Cr
About Corona Remedies
Corona Remedies Limited is an Indian pharmaceutical company established in 2004, focused on developing and marketing a wide range of branded formulations. The company was founded by Chandrakant Patel, who brought extensive experience from the domestic pharma industry. Over the years, Corona Remedies has built a strong presence in therapeutic segments such as women’s healthcare, cardiology, diabetology, pain management and anti-infectives. The company operates with a customer-centric approach, emphasising quality, innovation and accessibility of medicines. It has developed a robust distribution network across India, supported by a large field force that engages with healthcare professionals and institutions. By focusing on niche and high-growth segments, the company has been able to strengthen its brand recall and expand its footprint in the competitive pharmaceutical market. The company’s product portfolio consists primarily of branded generic medicines, including tablets, capsules, syrups and injectables, catering to both acute and chronic therapies. Corona Remedies follows an asset-light business model, where manufacturing is largely outsourced to WHO-GMP certified third-party facilities while it focuses on marketing, branding and distribution. This allows the company to maintain flexibility and control costs while ensuring consistent product quality. Its strategy revolves around launching differentiated products, building strong doctor relationships and expanding into new therapeutic areas. With a steady focus on research-backed marketing and efficient supply chain management, Corona Remedies aims to sustain long-term growth and strengthen its position in the Indian pharmaceutical industry.
Promoters and shareholding
Ankur Kirtikumar Mehta, Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta
- Promoter holding, pre-issue
- 72.5%
- Promoter holding, post-issue
- 69%
Registrar, lead managers and documents
Company contact
Registered office: 101 & 103, G V Royale, Near Galaxy Hotel, Off. F.G. Road, Akurdi, Pune, Maharashtra 411035.
+91 20 46702222.
cs@coronarememedies.comCorona Remedies IPO: common questions
1.When does the Corona Remedies IPO open and close?
The Corona Remedies IPO opens on 8 Dec 2025 and closes on 10 Dec 2025.
2.What is the price band of the Corona Remedies IPO?
The price band is ₹1,008 – ₹1,062 per share, with a lot size of 14 shares and a minimum investment of ₹14,868.
3.What is the size of the Corona Remedies IPO?
The issue size is ₹655.37 Cr (OFS only).
4.What is the GMP of the Corona Remedies IPO?
The last reported grey market premium is ₹300 per share as of 13 Jan 2026, 05:45 PM IST. GMP is unofficial and changes frequently.
5.When is the Corona Remedies IPO allotment?
The basis of allotment is expected on 11 Dec 2025. Allotment status can be checked with the registrar, KFin Technologies Limited.
6.When will the Corona Remedies IPO list?
The shares listed on 15 Dec 2025 on BSE, NSE.
7.Who is the lead manager of the Corona Remedies IPO?
The book running lead managers are JM Financial Ltd., Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, and the registrar is KFin Technologies Limited.
8.What will the money raised in the Corona Remedies IPO be used for?
As stated in the offer document, the proceeds are for: BRLMs fees and commissions (including underwriting commission, brokerage and selling commission); Fees payable to the Registrar to the Offer; Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank(s) for Bids made by RIIs using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs; Advertising and marketing expenses; Others.
9.How can my company launch an IPO like Corona Remedies?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393